FDA Authorizes Initiation of a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma Patients
Phase 2 study of cell therapy in trauma expands Company’s clinical programs focused on critical care CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ:...